Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2011. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than financial performance reporting.
Material Changes
Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan (notionally held in GSK Ordinary share ADRs), an increase in the notional allocation of Ordinary share ADRs occurred on April 1, 2011. The transaction price was $38.78 per ADR.
Management Commentary and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It is a procedural notification compliant with Disclosure and Transparency Rule 3.1.4R(1)(c).
Investor Verification Points
- Transaction Details: Verify the increase of 4 notional ADRs allocated to Dr. K. Belmonte on April 1, 2011.
- Valuation Price: Confirm the transaction price of $38.78 per ADR used for the re-valuation.
- Plan Structure: Note that the investment is held within the US Retirement Savings Plan as notional GSK Ordinary share ADRs.